Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
JSON
De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J, CORE-ARV-CTC and ProBIO Investigators
JAMA Oncol 5 (7) 1060-1062 [2019-07-01; online 2019-05-03]
Clinical Genomics Stockholm [Service]
PubMed 31046065
DOI 10.1001/jamaoncol.2019.0869
Crossref 10.1001/jamaoncol.2019.0869
pii: 2732501
pmc: PMC6499126